137 related articles for article (PubMed ID: 8402695)
1. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity.
Zhu GG; Risteli J; Puistola U; Kauppila A; Risteli L
Cancer Res; 1993 Oct; 53(20):5028-32. PubMed ID: 8402695
[TBL] [Abstract][Full Text] [Related]
2. Differential processing of type I and type III procollagens in the tumour cysts and peritoneal ascitic fluid of patients with benign and malignant ovarian tumours.
Zhu GG; Melkko J; Risteli J; Kauppila A; Risteli L
Clin Chim Acta; 1994 Sep; 229(1-2):87-97. PubMed ID: 7988058
[TBL] [Abstract][Full Text] [Related]
3. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas.
Kauppila S; Saarela J; Stenbäck F; Risteli J; Kauppila A; Risteli L
Am J Pathol; 1996 Feb; 148(2):539-48. PubMed ID: 8579116
[TBL] [Abstract][Full Text] [Related]
4. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma.
Tomás C; Risteli J; Risteli L; Vuori J; Kauppila A
Obstet Gynecol; 1991 Apr; 77(4):566-72. PubMed ID: 2002979
[TBL] [Abstract][Full Text] [Related]
5. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
6. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
[TBL] [Abstract][Full Text] [Related]
7. Type I and III procollagens in CAPD: markers of peritoneal fibrosis.
Joffe P; Jensen LT
Adv Perit Dial; 1991; 7():158-60. PubMed ID: 1680415
[TBL] [Abstract][Full Text] [Related]
8. Collagen metabolism in gynecologic patients: changes in the concentration of the aminoterminal propeptide of type III procollagen in serum.
Puistola U; Risteli L; Risteli J; Kauppila A
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1276-81. PubMed ID: 2220941
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer.
Santala M; Risteli J; Risteli L; Puistola U; Kacinski BM; Stanley ER; Kauppila A
Br J Cancer; 1998 Jun; 77(11):1825-31. PubMed ID: 9667653
[TBL] [Abstract][Full Text] [Related]
13. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
Wahlberg K; Høyer-Hansen G; Casslén B
Cancer Res; 1998 Aug; 58(15):3294-8. PubMed ID: 9699658
[TBL] [Abstract][Full Text] [Related]
14. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
15. Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarian tumours.
Haeger M; Swahn M; Hahlin M; Horvath G; Bengtsson A
Anticancer Res; 1996; 16(5B):3189-92. PubMed ID: 8967734
[TBL] [Abstract][Full Text] [Related]
16. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas.
Ott HW; Lindner H; Sarg B; Mueller-Holzner E; Abendstein B; Bergant A; Fessler S; Schwaerzler P; Zeimet A; Marth C; Illmensee K
Cancer Res; 2003 Nov; 63(21):7507-14. PubMed ID: 14612552
[TBL] [Abstract][Full Text] [Related]
17. Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer.
Kauppila A; Puistola U; Risteli J; Risteli L
Cancer Res; 1989 Apr; 49(7):1885-9. PubMed ID: 2924328
[TBL] [Abstract][Full Text] [Related]
18. Serum aminoterminal type III procollagen peptide. Relation to biosynthesis of collagen type III in experimentally induced granulation tissue in rats.
Hørslev-Petersen K; Kim KY; Pedersen LR; Bentsen KD; Uldbjerg N; Oxlund H; Garbarsch C; Hahn EG; Schuppan D; Lorenzen I
APMIS; 1988 Sep; 96(9):793-804. PubMed ID: 3048338
[TBL] [Abstract][Full Text] [Related]
19. Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo.
Kauppila S; Bode MK; Stenbäck F; Risteli L; Risteli J
Br J Cancer; 1999 Oct; 81(4):654-61. PubMed ID: 10574251
[TBL] [Abstract][Full Text] [Related]
20. Aminoterminal propeptide of type III procollagen in ovarian cancer. A review.
Risteli L; Risteli J; Puistola U; Tomás C; Zhu GG; Kauppila A
Acta Obstet Gynecol Scand Suppl; 1992; 155():99-103. PubMed ID: 1502898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]